Anti-tumor Efficacy of a Hepatocellular Carcinoma Vaccine Based on Dendritic Cells Combined with Tumor-derived Autophagosomes in Murine Models

  • Su, Shu (Cancer Research and Biotherapy Center, the Affiliated Nanjing Second Hospital, Medical School of Southeast University) ;
  • Zhou, Hao (Department of Microbiology and Immunology, Medical School of Southeast University) ;
  • Xue, Meng (Department of Microbiology and Immunology, Medical School of Southeast University) ;
  • Liu, Jing-Yu (Department of Microbiology and Immunology, Medical School of Southeast University) ;
  • Ding, Lei (Department of Microbiology and Immunology, Medical School of Southeast University) ;
  • Cao, Meng (Department of Microbiology and Immunology, Medical School of Southeast University) ;
  • Zhou, Zhen-Xian (Cancer Research and Biotherapy Center, the Affiliated Nanjing Second Hospital, Medical School of Southeast University) ;
  • Hu, Hong-Min (Cancer Research and Biotherapy Center, the Affiliated Nanjing Second Hospital, Medical School of Southeast University) ;
  • Wang, Li-Xin (Cancer Research and Biotherapy Center, the Affiliated Nanjing Second Hospital, Medical School of Southeast University)
  • Published : 2013.05.30


The majority of hepatocellular carcinoma (HCC) patients have a poor prognosis with current therapies, and new approaches are urgently needed. We have developed a novel therapeutic cancer vaccine platform based on tumor cell derived autophagosomes (DRibbles) for cancer immunotherapy. We here evaluated the effectiveness of DRibbles-pulsed dendritic cell (DC) immunization to induce anti-tumor immunity in BALB/c mouse HCC and humanized HCC mouse models generated by transplantation of human HCC cells (HepG2) into BALB/c-nu mice. DRibbles were enriched from H22 or BNL cells, BALB/c-derived HCC cell lines, by inducing autophagy and blocking protein degradation. DRibbles-pulsed DC immunization induced a specific T cell response against HCC and resulted in significant inhibition of tumor growth compared to mice treated with DCs alone. Antitumor efficacy of the DCs-DRibbles vaccine was also demonstrated in a humanized HCC mouse model. The results indicated that HCC/DRibbles-pulsed DCs immunotherapy might be useful for suppressing the growth of residual tumors after primary therapy of human HCC.


  1. Bosch FX, Ribes J, Borras J (1999). Epidemiology of primary liver cancer. Semin Liver Dis, 19, 271-85.
  2. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008). Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol, 9, 558-66.
  3. Butterfield LH (2004). Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology, 127, S232-41.
  4. Crotzer VL, Blum SJ (2009). Autophagy and Its Role in MHCMediated Antigen Presentation. J Immunol, 182, 3335-41.
  5. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
  6. Gilboa E (2007). DC-based cancer vaccines. J Clin Invest, 117, 1195-203.
  7. Grimm CF, Ortmann D, Mohr L, et al (2000). Mouse alphafetoprotein–specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology, 119, 1104-12.
  8. Gutierrez MG, Saka HA, Chinen I, et al (2007). Protective role of autophagy against vibrio cholera cytolysin, a pore-forming toxin from V cholerae. Proc Natl Acad Sci, 104, 1829-34.
  9. Joubert PE, Albert ML (2012). Antigen cross-priming of cell associated proteins is enhanced by macrophage within the antigen donor cell. Front Immunol, 3, 61.
  10. Kabeya Y, Mizushima N, Yamamoto A, et al (2004). LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci, 117, 2805-12.
  11. Karim MR, Kanazawa T, Daigaku Y, et al (2007). Cytosolic LC3 ratio as a sensitive index of macroautophagy in isolated rat hepatocytes and H4-II-E cells. Autophagy, 3, 553-60.
  12. Klionsky DJ, Emr SD (2000). Autophagy as a regulated pathway of cellular degradation. Science, 290, 1717-21.
  13. Kvistborg P, Boegh M, Pedersen AW, Claesson MH, Zocca MB (2009). Fast generation of dendritic cells. Cell Immunol, 260, 56-62.
  14. Li, Y, Wang LX, Yang G, et al (2008). Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res, 68, 6889-95.
  15. Li Y, Wang LX, Pang P, et al (2009). Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy, 5, 576-7.
  16. Li Y, Wang LX, Pang P, et al (2011). Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res, 17, 7047-57.
  17. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 359, 2497-9.
  18. Maraskovsky E, Brasel K, Teepe M, et al (1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med, 184, 1953-62.
  19. Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008). Autophagy fights disease through cellular self-digestion. Nature, 451, 1069-75.
  20. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2004). In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell, 15, 1101-11.
  21. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA (1998). Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science, 282, 480-3.
  22. Schreibelt G, Klinkenberg LJ, Cruz LJ, et al (2012). The C-type lectin receptor CLEC9A mediates antigen uptake and crosspresentation by human blood BDCA3+ myeloid dendritic cells. Blood, 119, 2284-92.
  23. Shen L, Rock KL (2006). Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol, 18, 85-91.
  24. Takayama T, Sekine T, Makuuchi M, et al (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 356, 802-7.
  25. Twitty CG, Jensen SM, Hu HM, Fox BA (2011). Tumor- derived autophagosome vaccine: induction of cross- protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res, 17, 6467-81.
  26. Yi Y, Zhou Z, Shu S, et al (2012). Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology, 1, 976-8.

Cited by

  1. Different Immunology Mechanisms of Phellinus igniarius in Inhibiting Growth of Liver Cancer and Melanoma Cells vol.15, pp.8, 2014,
  2. Trial watch vol.3, pp.6, 2014,
  3. Therapeutic Antitumor Efficacy of B Cells Loaded With Tumor-derived Autophagasomes Vaccine (DRibbles) vol.37, pp.8, 2014,
  4. Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells vol.11, pp.5, 2015,
  5. Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model vol.16, pp.10, 2015,
  6. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine vol.34, pp.1, 2015,
  7. Promising new strategies for hepatocellular carcinoma vol.47, pp.4, 2016,
  8. Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case report vol.5, pp.2, 2016,
  9. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers vol.13, pp.12, 2017,
  10. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma pp.1573-4919, 2017,
  11. Autophagy: A novel therapeutic target for hepatocarcinoma (Review) vol.7, pp.5, 2014,
  12. Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system vol.18, pp.1, 2018,